RDY
Dr Reddy's Laboratories Ltd
$12.56
▲ 0.2%Updated Today 3:42 PM ET
RDY at a glance — five pillars scored 0–100 from real filed financials.
Overall: Weak · 39/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▼ Down 5.2% over the last 12 months
Market Cap
$13.76B
P/E
27.33x
Forward P/E (est.)
36.8x
ROE
4.2%
Revenue Growth
3.2%
EPS Growth
-25.7%
Profit Margin
12.4%
FCF Yield
—
Debt / Equity
0.14x
ROIC
17.0%
Interest Coverage
24.8x
Current Ratio
1.92x
Dividend Yield
0.6%
Implied Growth (rev. DCF)
7.2%
Rating Score
39/100
Dr Reddy's Laboratories Ltd (RDY) is a large-cap company in the Pharmaceuticals industry, part of the Health Care sector of the S&P 500, with a market value around $13.76B.
In its latest reported year it generated about $3.91B in revenue and $686.94M in net profit.
Our model rates RDY Weak (39/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Evidence of durable competitive advantage in the filed financials (10 years of history).
The filed history looks like a business competitors struggle to attack: high and steady margins, revenue that grows through cycles, and strong returns on capital.
57.9% average over the last 3 years
±2.3 pts around 55.8% across 10 years
grew in 8 of the last 9 year-over-year periods
positive in 10 of 10 years
17.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what RDY's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. RDY trades near $12.56, below its 50-day average ($13.64) and 200-day average ($13.85). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 62 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. RDY's is $0.41 (~3.3% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month RDY found buyers near $13.08 (support) and sellers near $15.67 (resistance); its 52-week range is $12.19–$15.67. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.1× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
4Y CAGR
14.5%
Revenue moved from $1.86B in 2016 to $3.91B in 2025, a 8.6% compound annual growth rate. The most recent year was roughly flat (3.2%) year over year. Slower, mature growth is common for established businesses.
Gross Margin
58.5%
Operating Margin
22.1%
Net Margin
17.6%
ROE
4.2%
Dr Reddy's Laboratories Ltd keeps about 12.4% of each sales dollar as net profit, with a 58.5% gross margin and 22.1% operating margin. Return on equity is 4.2% and return on invested capital about 17.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$92.00M
Net Debt
-$80.00M
Net cash position
Net Debt / EBITDA
-0.09x
Debt / Equity
0.14x
Leverage: debt-to-equity is 0.1x, and operating profit covers interest about 24.8x, with a current ratio of 1.9x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $92.00M of total debt against $172.00M of cash.
Operating CF
$557.14M
Free Cash Flow
$227.09M
FCF Margin
5.8%
In the latest year Dr Reddy's Laboratories Ltd produced about $557.14M of operating cash flow and $227.09M of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.
The dividend is being paid, but coverage or consistency is thinner than an income investor should rely on without a closer look.
Dividend yield
0.6%
Per share (latest FY)
$0.48
Total paid (latest FY)
$79.94M
History on record
10 years
dividend uses 35% of free cash flow
12% of net income paid out
total dividends increased 3 years in a row
payout was cut at least once in the last 10 years
Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.
P/E
27.33x
P/S
3.4x
P/B
2.84x
EV / EBITDA
13.92x
RDY trades at 27.3x trailing earnings (about 36.8x on estimated forward earnings), 3.4x sales, and 2.8x book value. Reverse-engineering today's price implies the market expects roughly 7.2% long-term free-cash-flow growth. That is a premium multiple that needs growth to justify it.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$4.47
Current price
$12.56
Starting FCF (latest 10-K)
$227.09M
Growth, years 1–5
3.2%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where RDY sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How RDY stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), RDY ranks #65 of 324 by our overall rating. It trades at roughly in line versus the sector on earnings (27.3x P/E vs. 25.8x median) with a lower return on equity (4.2% vs. 14.1%) and slower revenue growth (3.2% vs. 7.6%).
P/E vs sector
27.3x
median 25.8x
ROE vs sector
4.2%
median 14.1%
Growth vs sector
3.2%
median 7.6%
Sector rank
#65
of 324 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $12.56 today · expected CAGR -1% – 10%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $4.02B | $4.14B | $4.27B | $4.40B | $4.53B |
| Net income | $724.25M | $745.98M | $768.36M | $791.41M | $815.15M |
| EPS | $0.66 | $0.68 | $0.70 | $0.72 | $0.74 |
| Share price (low) | $10.58 | $10.89 | $11.22 | $11.56 | $11.90 |
| Share price (high) | $17.85 | $18.38 | $18.94 | $19.50 | $20.09 |
| CAGR (low–high) | -16% / 42% | -7% / 21% | -4% / 15% | -2% / 12% | -1% / 10% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for RDY:
- A conservative balance sheet (debt/equity 0.1x) lowers risk.
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against RDY:
- Our model's overall read is Weak (39/100).
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen weakly: Dr Reddy's Laboratories Ltd is a large-cap health care business growing at a mature pace, with solid profitability, and a sound balance sheet. It trades at 27.3x earnings, which our model scores Weak (39/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 44 Wall Street analysts covering RDY recommend (July 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
RDY's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
In the Idea Lab
RDY — frequently asked questions
Is RDY a good stock to buy?
We don't give buy or sell advice. Our model rates Dr Reddy's Laboratories Ltd Weak (39/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is RDY's rating on The Stocks School?
Dr Reddy's Laboratories Ltd currently scores 39/100 (Weak) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does RDY's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Dr Reddy's Laboratories Ltd's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for RDY calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this RDY analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell RDY. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.